CD274 and non-small cell lung carcinoma: In conclusion, these findings have demonstrated an efficacy signal of interest with durvalumab–ceralasertib in advanced/metastatic NSCLC following prior failure of anti-PD-1/PD-L1 immunotherapy and platinum-doublet therapy.